Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 47
Filtrer
1.
Rev. méd. Chile ; 132(9): 1078-1084, sept. 2004. tab
Article de Espagnol | LILACS | ID: lil-443218

RÉSUMÉ

BACKGROUND: Exanthematic diseases are a group of syndromes mainly caused by acute viral infections. AIM: To obtain information about the viruses that cause exanthematic diseases in our region. PATIENTS AND METHODS: During 1998, 267 serum samples from patients with an acute rash or patients presenting a febrile syndrome accompanied by enlarged lymph nodes, headache and other symptoms, were collected. Specific antibody of the IgM class (anti-IgM) against Rubella, Measles, Dengue types 1-4 and Cytomegalovirus (CMV) were measured by immunoenzymatic assay (EIA). Epstein-Barr virus (EBV) antibodies were measured by immunofluorescence. RESULTS: An etiologic agent was detected in 208 cases (77.9%). Cases due to Dengue (40.6%) and Rubella (21%) viruses predominated, but the frequency of other agents was also high in specific age groups. The agreement between the clinical suspicion and the laboratory findings varied broadly, from a 100% for suspected Dengue to just a 14.8% for cases of suspected CMV infection. CONCLUSIONS: Dengue was the most common viral exanthematic disease in the Zulia State during 1998.


Sujet(s)
Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Enfant , Enfant d'âge préscolaire , Humains , Nourrisson , Adulte d'âge moyen , Exanthème/virologie , Dengue sévère/sang , Fièvre/virologie , Immunoglobuline M/sang , Loi du khi-deux , Maladie aigüe , Dengue sévère/complications , Infections à cytomégalovirus/sang , Infections à cytomégalovirus/complications , Rubéole/sang , Rubéole/complications , Syndrome , Venezuela
2.
Rev Gastroenterol Peru ; 21(4): 287-99, 2001.
Article de Espagnol | MEDLINE | ID: mdl-11818990

RÉSUMÉ

UNLABELLED: This study was done in patients with HIV infection and upper digestive symptoms as odinophagia, dysphagia and/or retrosternal pain who attended the Cayetano Heredia National Hospital in Lima, Perú. Those included in the study had an upper endoscopy and a CD4 count. Also previous opportunistic infections were determined. Samples were taken from the oropharyngeal cavity and sent for direct exam and culture. During endoscopy, photos were taken from the upper, middle, and lower third of the esophagus and the esophageal compromise was classified. Biopsies and brushings samples were obtained and sent for direct exam, histopathology and culture. RESULTS: 751 patients with HIV infection attended the Cayetano Heredia National Hospital between May 1996 and June 1999, 83 were included due to esophageal symptoms. Male / Female ratio : 4/1, mean age : 30.95 +/- 9.87. Cultures positive for Candida: 84.30% of esophageal biopsies samples, 88% of esophageal brushings and 60.2% of oropharyngeal cavity. The C. albicans species was isolated in 95.7% of biopsies, 93% of brushings and 96% of oropharyngeal cavity. The most common endoscopic finding was white plaques (71%), endoscopic grade 3 (36.1%). The most frequent previous opportunistic infection was PCP pneumonia followed by TBC. The positive predictive value for white plaques in patients with dysphagia and odynophagia was 89.8%. CD4 count between 0 and 50 lymphocytes per mm(3) was seen in 70% of the cases. The mean of CD4 lymphocytes of these patients was lower (p< 0.01) when compared to the mean of patients in the control group with no symptoms. CONCLUSIONS: Candida albicans was the most common isolated pathogen in the esophagus in patients with HIV infection and with esophageal symptoms, a significant difference in CD4 count between these patients and the control group was determined. The positive predictive value for finding esophageal white plaques in patients dysphagia and odinophagia was high, and there was no difference between the average of CD4 count and the endoscopic grade of esophageal involvement.


Sujet(s)
Maladies de l'oesophage/diagnostic , Oesophagoscopie , Infections à VIH/complications , Adulte , Femelle , Hôpitaux , Humains , Mâle
3.
Bol. Asoc. Méd. P. R ; Bol. Asoc. Méd. P. R;92(4/8): 83-88, Apr.-Aug. 2000.
Article de Anglais | LILACS | ID: lil-411268

RÉSUMÉ

In most hospitals in Puerto Rico the dying process of terminally ill patients is inappropriately prolonged. And this occurs often without the patient's consent and in violation of basic ethical principles. Three erroneous beliefs are prevalent: 1--That withdrawing life support therapy is morally or legally different from not starting it. 2--That there is a moral and legal difference between appropriate acts and appropriate omissions. 3--That good medical practice is determined by the courts instead of the medical profession. Institutional policies are not in harmony with contemporary medical ethics. To avoid possible legal entanglements medical institutions permit their faculties to prolong the suffering of patients in violation of two basic moral principles: nonmaleficence and respect for autonomy. An illustrative case provides a philosopher and a moral theologian the opportunity to analyze the applicable moral principles. A professor of jurisprudence reviews statutes evolved at the State and Federal level that support the rights of patients and their families to refuse unwanted treatments. Medical faculties must ensure that institutional policies do not violate their professional ethics. The medical profession and the citizenry at large should lobby for the passage of statutes in Puerto Rico which clearly validate the necessary harmony between medical ethics and the law


Sujet(s)
Humains , Mâle , Sujet âgé , Déontologie médicale , Sens moral , Ordres de réanimation , Consentement d'un tiers , Consentement d'un tiers/législation et jurisprudence , Inutilité médicale , Ordres de réanimation/législation et jurisprudence , Porto Rico , Religion et médecine
4.
Bol Asoc Med P R ; 92(4-8): 83-8, 2000.
Article de Anglais | MEDLINE | ID: mdl-11143825

RÉSUMÉ

In most hospitals in Puerto Rico the dying process of terminally ill patients is inappropriately prolonged. And this occurs often without the patient's consent and in violation of basic ethical principles. Three erroneous beliefs are prevalent: 1--That withdrawing life support therapy is morally or legally different from not starting it. 2--That there is a moral and legal difference between appropriate acts and appropriate omissions. 3--That good medical practice is determined by the courts instead of the medical profession. Institutional policies are not in harmony with contemporary medical ethics. To avoid possible legal entanglements medical institutions permit their faculties to prolong the suffering of patients in violation of two basic moral principles: nonmaleficence and respect for autonomy. An illustrative case provides a philosopher and a moral theologian the opportunity to analyze the applicable moral principles. A professor of jurisprudence reviews statutes evolved at the State and Federal level that support the rights of patients and their families to refuse unwanted treatments. Medical faculties must ensure that institutional policies do not violate their professional ethics. The medical profession and the citizenry at large should lobby for the passage of statutes in Puerto Rico which clearly validate the necessary harmony between medical ethics and the law.


Sujet(s)
Déontologie médicale , Sens moral , Ordres de réanimation , Consentement d'un tiers , Sujet âgé , Humains , Mâle , Inutilité médicale , Porto Rico , Religion et médecine , Ordres de réanimation/législation et jurisprudence , Consentement d'un tiers/législation et jurisprudence
5.
Rev Panam Salud Publica ; 5(3): 144-51, 1999 Mar.
Article de Espagnol | MEDLINE | ID: mdl-10355311

RÉSUMÉ

In Bolivia, no studies have been carried out specifically on hepatitis viruses. Thus, their prevalence and circulation patterns are virtually unknown. A seroepidemiologic study was performed from 1992 to 1996 to generate a preliminary idea of the overall prevalence of infection from hepatitis B, C, D, and E viruses (HBV, HCV, HDV, and HEV, respectively) in different Bolivian population groups. Prompted by the data obtained in other areas of Latin America, the study focused on indigenous communities in the Amazon region. In rural areas of the high Andean plateau, HBV infection showed an overall prevalence compatible with medium to low endemicity (11.2%), and no carriers of HCV or HDV antibodies were found. In two high-risk groups in the city of Cochabamba (homeless children and sexual workers), the prevalence of HBV infection was similar (11.6%) and could be considered low by comparison to that of similar population groups in Latin American urban centers. The prevalence of HCV (one positive case, or 0.5%) was similar to that found in similar population groups, although the small number of samples precludes drawing more definite conclusions. As has been noted previously with similar communities in tropical areas of South America, HBV infection is highly endemic in indigenous populations of the Bolivian Amazon (with an overall prevalence of 74.0%), but circulation of HCV has not been detected. It is a well-known fact that HBV is horizontally transmitted and that transmission can take place very early in life, but the mechanisms involved are unknown. By 10 years of age, more than half the population has already had the natural infection that, in approximately 10 more years will have affected virtually the entire population. The very low rate of positivity to HBsAg (1.6%), the absence of viral DNA in samples showing isolated positivity to anti-HBc, and the high prevalence of anti-HBs among individuals who show markers for natural infection (92.4%) suggest vertical transmission plays no role in persistent endemicity. So far, no outbreak of HDV infection has been documented in these communities, but the high endemicity shown by HBV points to the possibility of future outbreaks. Results obtained with tests for the detection of antibodies against HEV suggest that this virus is circulating widely in Bolivia and that it could have caused recent outbreaks in Cochabamba state. Vaccination against HBV in endemic populations is recommended as a short-term measure. Also recommended are actively searching for outbreaks and sporadic cases of hepatitis E in the entire country and performing additional research that will help in assessing the public health consequences of the situation described in this article.


Sujet(s)
Hépatite B/épidémiologie , Hépatite C/épidémiologie , Hépatite D/épidémiologie , Hépatite E/épidémiologie , Hépatites virales humaines/épidémiologie , Adolescent , Adulte , Bolivie/épidémiologie , Enfant , Enfant d'âge préscolaire , Femelle , Hépatite B/virologie , Hépatite C/virologie , Hépatite D/virologie , Hépatite E/virologie , Hépatites virales humaines/virologie , Humains , Nourrisson , Nouveau-né , Mâle , Prévalence
6.
J Clin Microbiol ; 36(3): 648-51, 1998 Mar.
Article de Anglais | MEDLINE | ID: mdl-9508289

RÉSUMÉ

The adw4 subtype of hepatitis B virus (HBV) belongs to a unique genomic group (genotype F) representing the original HBV strains from the New World. Data regarding the prevalence of this subtype among HBV carriers in South America are, however, scarce, and those concerning HBV genotype F are based on only a few samples from Latin America. In this study, serum samples were obtained from 141 hepatitis B surface antigen (HBsAg) carriers from Amerindians and urban populations from Venezuela. The HBsAg subtype was identified with monoclonal antibodies in 105 samples, and the HBV genotype was identified by reverse-phase hybridization with DNA fragments in 58 samples. The adw4 subtype was highly prevalent in the population studied (75%); among the Amerindians, the prevalence was 97%. The adw2 subtype was also present (10%), while other subtypes (ayw3 and ayw4) were only occasionally found. The HBV subtype was associated with the expected genotype in most cases (80%), and thus genotype F was highly prevalent. Sequencing of viral strains that gave genotypes unpredicted by the HBsAg subtyping confirmed seven of them as belonging to not previously described genotype-subtype associations: namely, adw2 and ayw4 within genotype F.


Sujet(s)
Variation des antigènes , Antigènes de surface du virus de l'hépatite B/génétique , Virus de l'hépatite B/génétique , Hépatite B/virologie , Indien Amérique Sud , Substitution d'acide aminé , Femelle , Génotype , Hépatite B/épidémiologie , Hépatite B/ethnologie , Antigènes de surface du virus de l'hépatite B/immunologie , Virus de l'hépatite B/classification , Virus de l'hépatite B/immunologie , Humains , Grossesse , Complications infectieuses de la grossesse/virologie , Analyse de séquence , Venezuela/épidémiologie
7.
Am J Trop Med Hyg ; 58(2): 192-4, 1998 Feb.
Article de Anglais | MEDLINE | ID: mdl-9502603

RÉSUMÉ

Leishmaniavirus is a double-stranded RNA virus that persistently infects some strains of the protozoan parasite Leishmania. There is considerable interest in the possibility that the presence of this virus alters parasite phenotype and may affect disease pathogenesis. If so, the virus marker could provide a valuable prognostic indicator for human leishmaniasis, particularly in those cases caused by New World parasite strains. The virus has been detected in cultured L. braziliensis, L. b. guyanensis, and L. major. To date there has been no information as to the extent of infection in samples prior to culturing in the laboratory. This study demonstrates, through the reverse transcription-polymerase chain reaction, that Leishmaniavirus exists in human biopsy samples of leishmaniasis prior to manipulation in culture.


Sujet(s)
Leishmaniose cutanée/virologie , Leishmaniavirus/isolement et purification , Peau/virologie , Animaux , Séquence nucléotidique , Ponction-biopsie à l'aiguille , Séquence consensus , ADN viral/analyse , ADN viral/composition chimique , Humains , Leishmaniose cutanée/étiologie , Leishmaniose cutanée/anatomopathologie , Leishmaniavirus/génétique , Leishmaniavirus/physiologie , Données de séquences moléculaires , Pérou , Réaction de polymérisation en chaîne , ARN viral/génétique , Analyse de séquence d'ADN
8.
Clin Infect Dis ; 25(3): 677-84, 1997 Sep.
Article de Anglais | MEDLINE | ID: mdl-9314461

RÉSUMÉ

A randomized, open, controlled clinical trial was designed to evaluate the efficacy, tolerance, and safety of sodium stibogluconate plus allopurinol and sodium stibogluconate alone as treatment of patients with mucocutaneous leishmaniasis. In phase 1 of the study, all 22 patients with severe disease had improvement of their lesions, but only two had clinical cure (both of these patients received sodium stibogluconate alone). In phase 2, which included 59 patients with moderate disease, the cure rate among sodium stibogluconate recipients was 75% (21 of 28) compared with 63.6% (14 of 22) among the sodium stibogluconate plus allopurinol recipients. The rates of clinical adverse events were similar among both groups. Thrombocytopenia was more frequent in the sodium stibogluconate plus allopurinol recipients, but the difference was not statistically significant. Eight patients (two sodium stibogluconate recipients and six sodium stibogluconate plus allopurinol recipients) withdrew from the study because of severe thrombocytopenia. In this study, the addition of allopurinol to sodium stibogluconate provided no clinical benefit as treatment of mucocutaneous leishmaniasis.


Sujet(s)
Allopurinol/administration et posologie , Gluconate d'antimoine et de sodium/administration et posologie , Antiprotozoaires/administration et posologie , Leishmaniose cutanéomuqueuse/traitement médicamenteux , Adulte , Allopurinol/effets indésirables , Gluconate d'antimoine et de sodium/effets indésirables , Antiprotozoaires/effets indésirables , Association de médicaments , Tolérance aux médicaments , Humains , Mâle , Sécurité
10.
Invest Clin ; 37(3): 191-200, 1996 Sep.
Article de Espagnol | MEDLINE | ID: mdl-8983357

RÉSUMÉ

After the report of the epidemic outbreak of delta hepatitis among the Yukpa amerindians in the early 80s, the viral hepatitis arose as an important health problem in all the Amerindian communities from the north of South America and the Amazonian Basin. Despite the few data available, the results obtained in different communities from Venezuela (Yukpa, Barí, Yanomami) have shown a high endemicity of hepatitis B and D virus infections and a significant prevalence of hepatitis E virus-specific antibody among their members. By contrast, the infection by hepatitis C virus, which is present in all the urban areas from South America, seems uncommon, or even absent among some Amerindian populations. At the moment, a satisfactory explanation for this findings has not yet been arised. However, it could be possible that the margination of these populations regarding the health care system has been keeping them free of an infection largely linked worldwide to iatrogeny. Vaccination of Amerindian populations against hepatitis B should be taken as a priority of the health care programs. Moreover, such programs should consider the iatrogenic transmission of the HCV as a matter of concern regarding such populations, since parenterally transmitted hepatitis viruses seems to spread quickly among their members once they are introduced, giving rise to serious health problems.


Sujet(s)
Hépatites virales humaines/épidémiologie , Indien Amérique Sud , Adulte , Hépatite C/épidémiologie , Hépatite C/prévention et contrôle , Hépatite C/transmission , Hépatites virales humaines/prévention et contrôle , Hépatites virales humaines/transmission , Humains , Maladie iatrogène , Injections/effets indésirables , Prévalence , Facteurs de risque , Amérique du Sud/épidémiologie , Vaccins contre les hépatites virales , Microbiologie de l'eau
11.
Clin Infect Dis ; 20(6): 1480-4, 1995 Jun.
Article de Anglais | MEDLINE | ID: mdl-7548495

RÉSUMÉ

We conducted a randomized double-blinded study in Lima, Peru, to assess the tolerability and efficacy of a single 250-mg dose of ciprofloxacin in preventing diarrhea and Vibrio cholerae O1 infection among household contacts of bacteriologically confirmed index cases. Adult household contacts with negative baseline stool cultures were included. A total of 213 household contacts were evaluable. The study drugs were well tolerated in both groups. Ciprofloxacin did not prevent the acquisition of V. cholerae O1 infection nor the development of diarrhea. However, in a subgroup of 30 household contacts with positive baseline stool cultures a reduction in the bacterial load and a trend toward prevention of diarrhea were observed among ciprofloxacin recipients. When all household contacts were evaluated, a trend toward prevention of diarrhea was observed with the prophylactic regimen. Ciprofloxacin failed to prevent V. cholerae O1 infections during a period of low transmissibility.


Sujet(s)
Choléra/prévention et contrôle , Ciprofloxacine/usage thérapeutique , Administration par voie orale , Adolescent , Adulte , Sujet âgé , Choléra/microbiologie , Ciprofloxacine/effets indésirables , Diarrhée/microbiologie , Diarrhée/prévention et contrôle , Méthode en double aveugle , Santé de la famille , Femelle , Humains , Mâle , Adulte d'âge moyen , Résultat thérapeutique
12.
Clin Infect Dis ; 20(6): 1485-90, 1995 Jun.
Article de Anglais | MEDLINE | ID: mdl-7548496

RÉSUMÉ

We conducted a randomized, double-blind clinical trial to compare ciprofloxacin (250 mg once a day for 3 days) with tetracycline (500 mg four times a day for 3 days) in terms of efficacy and safety in the treatment of moderate-to-severe cholera in Peruvian adults. The baseline characteristics of the groups were similar. A total of 202 patients (102 in the tetracycline group and 100 in the ciprofloxacin group) were included in the efficacy analysis. The clinical and bacteriologic efficacies of the two regimens were similar. The study drugs were well tolerated. We conclude that ciprofloxacin given once a day is as effective as the standard tetracycline regimen for the treatment of cholera in adults. The ciprofloxacin regimen may represent an alternative to the standard treatment in areas where Vibrio cholerae O1 strains that are resistant to commonly used antimicrobials are prevalent.


Sujet(s)
Choléra/traitement médicamenteux , Ciprofloxacine/usage thérapeutique , Administration par voie orale , Adolescent , Adulte , Sujet âgé , Choléra/microbiologie , Ciprofloxacine/effets indésirables , Méthode en double aveugle , Calendrier d'administration des médicaments , Femelle , Humains , Mâle , Adulte d'âge moyen , Pérou , Tétracycline/usage thérapeutique , Résultat thérapeutique
14.
Am J Trop Med Hyg ; 51(1): 77-82, 1994 Jul.
Article de Anglais | MEDLINE | ID: mdl-8059918

RÉSUMÉ

The efficacy and toxicity of two regimens of antimony, 28 and 40 days of 20 mg of antimony/kg/day, were compared in the treatment of culture-positive mucosal leishmaniasis involving more than one anatomic site. Forty consecutive eligible Peruvians with infiltrative or ulcerative mucosal disease of the lips, nose, palate-uvula-pharynx, or larynx-epiglottis were randomized to receive either 28 days (P28) or 40 days (P40) of sodium stibogluconate (Pentostam). Treatment was prematurely terminated due to thrombocytopenia in three patients and two patients did not complete six months of follow-up. At one month post-treatment, 13% (2 of 16) of the P28 patients and 16% (3 of 19) of the P40 patients no longer had infiltrates or ulcers and were initially considered cured. During a further 11 months of follow-up, infiltrated lesions healed in eight more P28 patients and in 10 more P40 patients. The cure rate after 12 months of follow-up was therefore 63% for both groups (10 of 16 in the P28 group and 12 of 19 in the P40 group). The total of 13 patients who had infiltrates or ulcers at the 9-12-month follow-up were considered failures. All seven patients (three in the P28 group and four in the P40 group) whose lesions were culture-positive for Leishmania at some point in the 12 months after treatment, and who were thereby parasitologic failures, were also clinical failures.(ABSTRACT TRUNCATED AT 250 WORDS)


Sujet(s)
Gluconate d'antimoine et de sodium/usage thérapeutique , Leishmaniose cutanéomuqueuse/traitement médicamenteux , Maladies professionnelles/traitement médicamenteux , Adulte , Gluconate d'antimoine et de sodium/administration et posologie , Gluconate d'antimoine et de sodium/effets indésirables , Calendrier d'administration des médicaments , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Pérou , Résultat thérapeutique
15.
J Med Virol ; 43(3): 287-90, 1994 Jul.
Article de Anglais | MEDLINE | ID: mdl-7523583

RÉSUMÉ

Hepatitis C virus (HCV) is transmitted mainly by the parenteral route after percutaneous exposure to virus-infected products or body fluids. Thus, HCV shares with hepatitis B and D (HBV, HDV) viruses this common transmission route. The prevalence of antibody against HCV (anti-HCV) was studied in 1155 serum samples from individuals at risk of infection by bloodborne or sexually transmitted agents, as well as from others lacking such risk factors, from the city of Maracaibo, Venezuela. Anti-HCV and serological markers of infection by HBV and HDV were also studied in further 550 samples taken from Bari Indians living in different communities in the Perijá mountains, State of Zulia, Venezuela. The results obtained showed that recipients of blood or blood products are at increased risk of HCV infection in Maracaibo, whereas sexual transmission plays only a minor role if any. Both HBV and HDV infections were highly prevalent among Bari Indians (64.4% positive for anti-HBc; 11.1% of HBsAg carriers; 15.3% positive for anti-HDV among HBsAg carriers). No anti-HCV positive samples were, however, detected among them, thus suggesting either that HCV has not still reached this population or that HBV and HDV are transmitted by routes unshared by HCV. Anti-HCV was also absent among samples from mentally retarded patients from Maracaibo, thus confirming similar findings from other countries and supporting the existence of specific transmission mechanisms for HBV and HDV which are not working for HCV.


Sujet(s)
Hépatite C/épidémiologie , Spécificité des anticorps , Marqueurs biologiques , Femelle , Hepacivirus/immunologie , Anticorps de l'hépatite/sang , Hépatite B/épidémiologie , Hépatite C/immunologie , Hépatite C/transmission , Anticorps de l'hépatite C , Hépatite D/épidémiologie , Humains , Indien Amérique Sud , Mâle , Grossesse , Études séroépidémiologiques , Venezuela/épidémiologie
16.
Kidney Int ; 40(2): 302-8, 1991 Aug.
Article de Anglais | MEDLINE | ID: mdl-1942779

RÉSUMÉ

It has been suggested that salt loading protects against amphotericin B-induced nephrotoxicity. The influence of saline loading on the nephrotoxic response to amphotericin B (50 mg/dose given i.v. over 4 hr 3 X/week for 10 weeks) was assessed in two groups of ten patients each who were diagnosed with mucocutaneous leishmaniasis. Patients were randomized to receive either 1 liter of 0.9% saline or 1 liter of 5% dextrose in water, administered i.v. over one hour in a double-blinded manner, directly prior to amphotericin B administration. Renal function was monitored on a weekly basis two days after the last dose of amphotericin B. Baseline characteristics were similar in both groups except for a slightly higher serum creatinine concentration (Cr) in the saline group (0.8 +/- 0.05 vs. 0.6 +/- 0.04 mg/dl). Baseline sodium (Na) excretion was relatively high (262 +/- 23 mmol/day in the dextrose group and 224 +/- 17 mmol/day in the saline group). None of the patients sustained an increase in Cr to values greater than 1.7 mg/dl. Although mean Cr remained within normal, there was a significant difference between the two groups over the ten week period, with the dextrose group sustaining a significant increase in Cr and the saline group remaining unchanged. Serum potassium (K) levels fell in both groups necessitating oral K supplementation. The saline group required significantly greater amounts of K supplementation to maintain a normal serum K. Amphotericin B caused a rapid reduction in the acidification ability of the kidney in response to an ammonium chloride load. Under these conditions, the saline group had a poorer ability to acidify the urine.(ABSTRACT TRUNCATED AT 250 WORDS)


Sujet(s)
Amphotéricine B/antagonistes et inhibiteurs , Rein/effets des médicaments et des substances chimiques , Chlorure de sodium/administration et posologie , Adolescent , Adulte , Sujet âgé , Amphotéricine B/effets indésirables , Amphotéricine B/métabolisme , Créatinine/sang , Débit de filtration glomérulaire/effets des médicaments et des substances chimiques , Humains , Rein/physiopathologie , Leishmaniose cutanéomuqueuse/sang , Leishmaniose cutanéomuqueuse/traitement médicamenteux , Adulte d'âge moyen , Potassium/sang
17.
Fontilles, Rev. leprol ; 17(3): 237-250, Sep.-Dic. 1989. ilus, tab
Article de Espagnol | Sec. Est. Saúde SP, HANSEN, Hanseníase Leprosy, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1225588

RÉSUMÉ

Examinamos 37 pacientes diagnosticados de lepra estudiando sus lesiones uveales cristalinas y esclerales. De ellos 31 eran formas lepromatosas, 2 borderline lepromatosas , 2 borderline tuberculoide y 2 tuberculoides. En 6 casos no encontramos lesiones de ningún tipo. En los restantes casos observamos una disminución de la agudeza visual directamente relacionada con la duración de la enfermedad. Las uveites crónicas indolentes fueron la causa más importante de ceguera, de las mismas fueron signos típicos la atrofia iridiana peripupilar, los precipitados queráticos, las sinequias posteriores y la miosis. Un número sorprendentemente elevado de pacientes presentaban ptisis bulbi uni o bilateral por atrofia del cuerpo ciliar. Las lesiones esclerales estuvieron representadas por escleritis, episcleritis en los casos agudos. La ectasia y adelgazamiento escleral aparecieron como secuelas de la anteriores en menor número de pacientes. No hemos encontrado lesiones funduscópicas.


Sujet(s)
Lèpre/complications
18.
Fontilles, Rev. leprol ; 17(1): 31-40, Ene.-May. 1989. ilus, tab
Article de Espagnol | Sec. Est. Saúde SP, HANSEN, Hanseníase Leprosy, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1225576

RÉSUMÉ

Se presenta un caso de lepra dimorfa en un varón de 13 años, con múltiples lesiones cutáneas, placas, nódulos, pápilas, alopecia y neuropatía periférica. Bacilospopía positiva. Se le clasifica com BT con "downgrading reaction". A los 3 años del control persisten escasas lesiones, la bacteriología es negativa. Se hacen consideraciones sobre la inestabilidad y la frecuente evolúción sin terapéutica adecuada hacia el polo lepromatoso.


Sujet(s)
Lèpre interpolaire/complications , Lèpre/classification
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE